{"protocolSection":{"identificationModule":{"nctId":"NCT01005680","orgStudyIdInfo":{"id":"12878"},"secondaryIdInfos":[{"id":"H3E-CR-JMIL","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer","officialTitle":"A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer."},"statusModule":{"statusVerifiedDate":"2013-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-11"},"primaryCompletionDateStruct":{"date":"2012-11","type":"ACTUAL"},"completionDateStruct":{"date":"2012-11","type":"ACTUAL"},"studyFirstSubmitDate":"2009-10-29","studyFirstSubmitQcDate":"2009-10-29","studyFirstPostDateStruct":{"date":"2009-11-02","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-10-18","resultsFirstSubmitQcDate":"2013-10-18","resultsFirstPostDateStruct":{"date":"2013-12-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-10-18","lastUpdatePostDateStruct":{"date":"2013-12-13","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC)."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":256,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed plus Cisplatin","type":"EXPERIMENTAL","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin"]},{"label":"Gemcitabine plus Cisplatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Gemcitabine","Drug: Cisplatin"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed","description":"500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles","armGroupLabels":["Pemetrexed plus Cisplatin"],"otherNames":["Alimta","LY231514"]},{"type":"DRUG","name":"Gemcitabine","description":"1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles","armGroupLabels":["Gemcitabine plus Cisplatin"],"otherNames":["Gemzar","LY188011"]},{"type":"DRUG","name":"Cisplatin","description":"75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles","armGroupLabels":["Gemcitabine plus Cisplatin","Pemetrexed plus Cisplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was defined as the duration from date of randomization to date of death from any cause. Participants who were alive were censored at the date of last contact.","timeFrame":"Randomization to date of death from any cause up to 35.8 months post-randomization"}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS)","description":"PFS was defined as the date of randomization to date of first observation of clinical or objective progressive disease (PD) or death due to any cause. PD assessed using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of one or more new lesions. Participants who were not known to have died or had PD were censored at the date of last contact.","timeFrame":"Randomization to first date of Progressive Disease (PD) or death from any cause up to 33.0 months post-randomization"},{"measure":"Time to Progressive Disease (TtPD)","description":"TtPD defined as the time from study randomization to the first date of progressive disease (PD). PD assessed using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions. Participants who were not known to have PD or who died without PD were censored at the date of last of last tumor assessment.","timeFrame":"Randomization to first date of PD up to 23.7 months post-randomization"},{"measure":"Duration of Response (DoR)","description":"DoR was defined as the time from first objective status assessment of complete response (CR) or partial response (PR) to the first time progressive disease (PD) or death as a result of any cause. Response using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Participants who are not known to have died or to have PD were censored at the date of last contact. PD assessed using RECIST v1.0 and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions","timeFrame":"Date of first response to the date of (PD) or death from any cause up to 22.9 months post-randomization"},{"measure":"Time to Treatment Failure (TtTF)","description":"TtTF was defined as date of randomization until the date of discontinuation of study treatment due to adverse event, progressive disease (PD), or death from any cause. PD assessed using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions. Participants who discontinued study treatment for any other reason were censored at the date of discontinuation of study treatment. Participants still on study drug at data-inclusion cut-off date were censored at the cut-off date.","timeFrame":"Randomization until date of discontinuation of study treatment due to adverse events, PD, or death from any cause up to 6.3 months post-randomization"},{"measure":"Tumor Response Rate","description":"Tumor response rate was the percentage of participants with confirmed best tumor response of complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions; Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions. Progressive disease (PD) assessed using RECIST v1.0 criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions.","timeFrame":"Randomization until date of objective PD or death from any cause up to 35.8 months post-randomization"},{"measure":"Risk/Benefit Ratio","description":"Risk/benefit ratio was calculated as the percentage of participants who experienced a study-drug related toxicity of Common Terminology Criteria for Adverse Events (CTCAE v3.0) Cancer Therapy Evaluation Program (CTEP) Grade 3 or higher, divided by the Kaplan-Meier estimated percentage of participants surviving one year.","timeFrame":"Randomization to date of death from any cause up to 35.8 months post-randomization"}],"otherOutcomes":[{"measure":"Disease Control Rate (DCR)","description":"DCR was the percentage of participants with Complete Response (CR), Partial Response (PR), and Stable Disease (SD). Response determined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions; progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions; SD was defined as small changes that did not meet the above criteria.","timeFrame":"Randomization to date of objective PD or death from any cause up to 35.8 months post-randomization"},{"measure":"Survival Without Toxicity (SWT)","description":"SWT was defined as the time from randomization to a study-drug related toxicity. Toxicity was defined as Common Terminology Criteria for Adverse Events (CTCAE v3.0) Grade 3 or 4 or death. Participants who do not have a CTCAE Grade 3 or higher toxicity and are alive will be censored at the date of last contact.","timeFrame":"Randomization to date of toxicity or date of death up to 34.6 months post-randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Present with histologically proven or cytological diagnosis of non-squamous non-small cell lung cancer (NSCLC) Stage IIIB or IV.\n* Participants must agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug.\n* Female participants must not be pregnant.\n* No prior systemic chemotherapy for lung cancer.\n* At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors.\n* Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.\n* Adequate organ function.\n* Prior radiation therapy allowed to \\<25% of the bone marrow.\n* Signed informed consent document on file.\n* Estimated life expectancy of greater than or equal to 12 weeks.\n* Participant compliance and geographic proximity that allow adequate follow up.\n\nExclusion Criteria:\n\n* Peripheral neuropathy of great than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1.\n* Inability to comply with protocol or study procedures.\n* A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to complete the study.\n* A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.\n* Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.\n* Documented brain metastases unless the participant has completed successful local therapy for central nervous system metastases and has not taken corticosteroids for at least 4 weeks before enrollment.\n* Presence of clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.\n* Significant weight loss (that is, greater than or equal to 10%) over the previous 6 weeks before study entry.\n* Concurrent administration of any other anti-tumor therapy.\n* Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents, such as piroxicam).\n* Inability or unwillingness to take folic acid or vitamin B12 supplementation.\n* Inability to take corticosteroids.\n* Pregnant or breast-feeding.\n* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Beijing","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Changchun","zip":"130012","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dalian","zip":"116023","country":"China","geoPoint":{"lat":38.91222,"lon":121.60222}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guangzhou","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nanjing","zip":"210002","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nanning","zip":"530000","country":"China","geoPoint":{"lat":22.81667,"lon":108.31667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shanghai","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sichuan","zip":"610041","country":"China","geoPoint":{"lat":35.1221,"lon":105.48032}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"FG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"126"},{"groupId":"FG001","numSubjects":"130"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"125"},{"groupId":"FG001","numSubjects":"127"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"120"},{"groupId":"FG001","numSubjects":"119"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"11"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on day 1 of each 21-day cycle, for 6 cycles"},{"id":"BG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"256"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.6","spread":"10.65"},{"groupId":"BG001","value":"55.7","spread":"9.95"},{"groupId":"BG002","value":"56.1","spread":"10.29"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"114"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"142"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"256"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"256"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"256"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS was defined as the duration from date of randomization to date of death from any cause. Participants who were alive were censored at the date of last contact.","populationDescription":"Intent-to-Treat: all participants and are analyzed according to the treatment group they were randomly assigned. Censored participants: PC=37, GC=39.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to date of death from any cause up to 35.8 months post-randomization","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"OG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"130"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.54","lowerLimit":"13.34","upperLimit":"22.67"},{"groupId":"OG001","value":"15.51","lowerLimit":"13.70","upperLimit":"19.29"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.822","pValueComment":"HR adjusted for treatment, disease stage, Eastern Cooperative Oncology Group Performance Status (ECOG PS), sex, and basis for initial pathological diagnosis.","statisticalMethod":"Cox Proportional Hazard","paramType":"Hazard Ratio (HR)","paramValue":"1.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"1.39"}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS was defined as the date of randomization to date of first observation of clinical or objective progressive disease (PD) or death due to any cause. PD assessed using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of one or more new lesions. Participants who were not known to have died or had PD were censored at the date of last contact.","populationDescription":"Intent-to-Treat: all randomized participants who are analyzed according to the treatment group they were randomly assigned. Censored participants: PC=8, GC=10.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to first date of Progressive Disease (PD) or death from any cause up to 33.0 months post-randomization","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"OG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"130"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.88","lowerLimit":"4.99","upperLimit":"6.47"},{"groupId":"OG001","value":"5.85","lowerLimit":"5.59","upperLimit":"6.41"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.640","pValueComment":"HR adjusted for treatment, disease stage, Eastern Cooperative Oncology Group Performance Status (ECOG PS), sex and basis for initial pathological diagnosis.","statisticalMethod":"Cox Proportional Hazard","paramType":"Hazard Ratio (HR)","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.82","ciUpperLimit":"1.37"}]},{"type":"SECONDARY","title":"Time to Progressive Disease (TtPD)","description":"TtPD defined as the time from study randomization to the first date of progressive disease (PD). PD assessed using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions. Participants who were not known to have PD or who died without PD were censored at the date of last of last tumor assessment.","populationDescription":"Intent-to-Treat: all randomized participants who were analyzed according to the treatment group they were randomly assigned. Censored participants: PC=12, GC=19.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to first date of PD up to 23.7 months post-randomization","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"OG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"130"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.82","lowerLimit":"4.76","upperLimit":"6.47"},{"groupId":"OG001","value":"5.82","lowerLimit":"5.55","upperLimit":"6.34"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.928","pValueComment":"HR adjusted for treatment, disease stage, Eastern Cooperative Oncology Group Performance Status (ECOG PS), sex and biases for initial pathological diagnosis.","statisticalMethod":"Cox Proportional Hazard","paramType":"Hazard Ratio (HR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.78","ciUpperLimit":"1.32"}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"DoR was defined as the time from first objective status assessment of complete response (CR) or partial response (PR) to the first time progressive disease (PD) or death as a result of any cause. Response using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Participants who are not known to have died or to have PD were censored at the date of last contact. PD assessed using RECIST v1.0 and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions","populationDescription":"Intent-to-Treat: all randomized participants who were analyzed according to the treatment group they were randomly assigned and who achieved CR or PR. Censored participants: PC=1, GC=0.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Date of first response to the date of (PD) or death from any cause up to 22.9 months post-randomization","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"OG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.53","lowerLimit":"4.17","upperLimit":"5.88"},{"groupId":"OG001","value":"4.98","lowerLimit":"3.55","upperLimit":"6.41"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.887","pValueComment":"HR adjusted for treatment, disease stage, Eastern Cooperative Oncology Group Performance Status (ECOG PS), sex and basis for initial pathological diagnosis.","statisticalMethod":"Cox Proportional Hazard","paramType":"Hazard Ratio (HR)","paramValue":"0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.51","ciUpperLimit":"1.79"}]},{"type":"SECONDARY","title":"Time to Treatment Failure (TtTF)","description":"TtTF was defined as date of randomization until the date of discontinuation of study treatment due to adverse event, progressive disease (PD), or death from any cause. PD assessed using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions. Participants who discontinued study treatment for any other reason were censored at the date of discontinuation of study treatment. Participants still on study drug at data-inclusion cut-off date were censored at the cut-off date.","populationDescription":"Intent-to-Treat: all randomized participants who were analyzed according to the treatment group they were randomly assigned. Censored participants: PC=85, GC=91.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization until date of discontinuation of study treatment due to adverse events, PD, or death from any cause up to 6.3 months post-randomization","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"OG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"130"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Results were not calculable due to high censoring rate."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Results were not calculable due to high censoring rate."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.861","pValueComment":"HR adjusted for treatment, disease stage, Eastern Cooperative Oncology Group Performance Status (ECOG PS), sex and basis for initial pathological diagnosis.","statisticalMethod":"Cox Proportional Hazard","paramType":"Hazard Ratio (HR)","paramValue":"1.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.67","ciUpperLimit":"1.61"}]},{"type":"SECONDARY","title":"Tumor Response Rate","description":"Tumor response rate was the percentage of participants with confirmed best tumor response of complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions; Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions. Progressive disease (PD) assessed using RECIST v1.0 criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions.","populationDescription":"Tumor Response-Qualified Population: all randomized participants who received at least l dose of study drug, who were diagnosed with locally advanced/metastatic non-small cell lung cancer, who had at least 1 baseline and 1 post-baseline tumor measurement, and who were not on concurrent systemic chemotherapy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Randomization until date of objective PD or death from any cause up to 35.8 months post-randomization","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"OG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"116"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8"},{"groupId":"OG001","value":"20.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.451","statisticalMethod":"two-sided Z test","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Risk/Benefit Ratio","description":"Risk/benefit ratio was calculated as the percentage of participants who experienced a study-drug related toxicity of Common Terminology Criteria for Adverse Events (CTCAE v3.0) Cancer Therapy Evaluation Program (CTEP) Grade 3 or higher, divided by the Kaplan-Meier estimated percentage of participants surviving one year.","populationDescription":"Safety population: all randomized participants who received at least 1 dose of study drug and were analyzed according to actual treatment received in Cycle 1 of 21-day cycle.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"ratio","timeFrame":"Randomization to date of death from any cause up to 35.8 months post-randomization","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"OG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"127"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70"},{"groupId":"OG001","value":"0.83"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Disease Control Rate (DCR)","description":"DCR was the percentage of participants with Complete Response (CR), Partial Response (PR), and Stable Disease (SD). Response determined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions; progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions; SD was defined as small changes that did not meet the above criteria.","populationDescription":"Tumor Response Qualified Population: all randomized participants who received at least l dose of study drug, who were diagnosed with locally advanced/metastatic non-small cell lung cancer, who had at least 1 baseline and 1 post-baseline tumor measurement, and who are not on concurrent systemic chemotherapy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Randomization to date of objective PD or death from any cause up to 35.8 months post-randomization","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"OG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"116"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5"},{"groupId":"OG001","value":"75.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.627","statisticalMethod":"two-sided Z test","ciPctValue":"95"}]},{"type":"OTHER_PRE_SPECIFIED","title":"Survival Without Toxicity (SWT)","description":"SWT was defined as the time from randomization to a study-drug related toxicity. Toxicity was defined as Common Terminology Criteria for Adverse Events (CTCAE v3.0) Grade 3 or 4 or death. Participants who do not have a CTCAE Grade 3 or higher toxicity and are alive will be censored at the date of last contact.","populationDescription":"Safety population: all randomized participants who received at least 1 dose of study drug and were analyzed according to actual treatment received in Cycle 1 of 21-day cycles. Censored participants: PC=22, GC=10.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to date of toxicity or date of death up to 34.6 months post-randomization","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"},{"id":"OG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"127"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.85","lowerLimit":"4.21","upperLimit":"8.38"},{"groupId":"OG001","value":"2.56","lowerLimit":"1.68","upperLimit":"3.78"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed Plus Cisplatin (PC)","description":"Pemetrexed: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on day 1 of each 21-day cycle, for 6 cycles","seriousNumAffected":8,"seriousNumAtRisk":125,"otherNumAffected":120,"otherNumAtRisk":125},{"id":"EG001","title":"Gemcitabine Plus Cisplatin (GC)","description":"Gemcitabine: 1250 mg/m² administered intravenously on Day 1 and day 8 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles","seriousNumAffected":9,"seriousNumAtRisk":127,"otherNumAffected":123,"otherNumAtRisk":127}],"seriousEvents":[{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":127}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":127}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":127}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":127}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":127}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":125},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":127}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":127}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":127}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":127}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":127}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":127}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":127}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":127}]},{"term":"Embolism venous","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":127}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":127}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":127}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":125},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":127}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":28,"numAtRisk":125},{"groupId":"EG001","numEvents":54,"numAffected":44,"numAtRisk":127}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":101,"numAffected":53,"numAtRisk":125},{"groupId":"EG001","numEvents":142,"numAffected":60,"numAtRisk":127}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":125},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":127}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":122,"numAffected":52,"numAtRisk":125},{"groupId":"EG001","numEvents":148,"numAffected":65,"numAtRisk":127}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":10,"numAtRisk":125},{"groupId":"EG001","numEvents":23,"numAffected":13,"numAtRisk":127}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":21,"numAtRisk":125},{"groupId":"EG001","numEvents":47,"numAffected":32,"numAtRisk":127}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":125},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":127}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":125},{"groupId":"EG001","numEvents":12,"numAffected":8,"numAtRisk":127}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":132,"numAffected":56,"numAtRisk":125},{"groupId":"EG001","numEvents":131,"numAffected":59,"numAtRisk":127}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":95,"numAffected":44,"numAtRisk":125},{"groupId":"EG001","numEvents":88,"numAffected":54,"numAtRisk":127}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":33,"numAtRisk":125},{"groupId":"EG001","numEvents":55,"numAffected":33,"numAtRisk":127}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":125},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":127}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":25,"numAtRisk":125},{"groupId":"EG001","numEvents":32,"numAffected":24,"numAtRisk":127}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":20,"numAtRisk":125},{"groupId":"EG001","numEvents":20,"numAffected":13,"numAtRisk":127}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":125},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":127}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":10,"numAtRisk":125},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":127}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":21,"numAtRisk":125},{"groupId":"EG001","numEvents":47,"numAffected":33,"numAtRisk":127}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":28,"numAtRisk":125},{"groupId":"EG001","numEvents":68,"numAffected":30,"numAtRisk":127}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":125},{"groupId":"EG001","numEvents":28,"numAffected":16,"numAtRisk":127}]},{"term":"Red blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":125},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":127}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":25,"numAtRisk":125},{"groupId":"EG001","numEvents":68,"numAffected":32,"numAtRisk":127}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":88,"numAffected":46,"numAtRisk":125},{"groupId":"EG001","numEvents":67,"numAffected":39,"numAtRisk":127}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":125},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":127}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":17,"numAtRisk":125},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":127}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":125},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":127}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":125},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":127}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":125},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":127}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":125},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":127}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D002945","term":"Cisplatin"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"}]}},"hasResults":true}